Edwards Lifesciences Corp Short Interest Down 40.9% in April (EW)
Edwards Lifesciences Corp (NYSE:EW) was the target of a significant drop in short interest during the month of April. As of April 30th, there was short interest totalling 4,910,229 shares, a drop of 40.9% from the April 15th total of 8,306,637 shares, ARN reports. Currently, 4.6% of the company’s shares are sold short. Based on an average trading volume of 1,326,037 shares, the short-interest ratio is presently 3.7 days.
A number of research firms have recently commented on EW. Analysts at CRT Capital raised their price target on shares of Edwards Lifesciences Corp from $87.00 to $90.00 in a research note on Thursday. They now have a “buy” rating on the stock. Separately, analysts at Canaccord Genuity raised their price target on shares of Edwards Lifesciences Corp from $86.00 to $96.00 in a research note on Wednesday, May 21st. They now have a “buy” rating on the stock. Finally, analysts at Leerink Swann raised their price target on shares of Edwards Lifesciences Corp from $90.00 to $93.00 in a research note on Friday, May 9th. Six research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $81.69.
Edwards Lifesciences Corp (NYSE:EW) opened at 80.77 on Monday. Edwards Lifesciences Corp has a one year low of $60.62 and a one year high of $87.03. The stock has a 50-day moving average of $81.14 and a 200-day moving average of $70.93. The company has a market cap of $8.521 billion and a P/E ratio of 29.57.
Edwards Lifesciences Corp (NYSE:EW) last issued its quarterly earnings data on Thursday, April 24th. The company reported $0.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.07. The company had revenue of $522.40 million for the quarter, compared to the consensus estimate of $523.10 million. During the same quarter in the previous year, the company posted $0.72 earnings per share. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. Analysts expect that Edwards Lifesciences Corp will post $3.15 EPS for the current fiscal year.
Edwards Lifesciences Corporation (NYSE:EW) is focused on technologies that treat structural heart disease and critically ill patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.